AI Article Synopsis
Article Abstract
Inflammatory bowel disease (IBD), comprising Crohn's disease and ulcerative colitis, is a chronic inflammatory condition of the gastrointestinal tract, which is often accompanied by altered gut microbial composition. Gut dysbiosis in IBD is considered to be the reason for the high risk of infection (CDI) in patients with IBD. Therefore, CDI should be evaluated in IBD patients with a symptom flare. Medical treatment of non-severe CDI in IBD is similar to that in non-IBD patients and includes oral vancomycin or fidaxomicin. The risk of recurrent CDI in IBD is higher than in non-IBD patients and this could be mitigated by fecal microbiota transplantation. As CDI may worsen the clinical outcomes of IBD, patients should be carefully monitored and an escalation of IBD therapy needs to be considered when there is no improvement seen with the antimicrobial treatment of CDI. This review discusses the risk, pathophysiology, diagnosis, and management of CDI in IBD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4166/kjg.2022.097 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis of risk factors of infection in patients with inflammatory bowel disease.
Prz Gastroenterol
September 2024
Department of Internal Medicine and Gastroenterology with Inflammatory Bowel Disease Unit, National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland.
Introduction: infection (CDI) is one of the most important challenges in contemporary gastroenterology. However, data from CDI studies are sometimes contradictory.
Aim: To analyse the risk factors for CDI in patients with inflammatory bowel disease (IBD).
Prevalence and sequelae of asymptomatic Clostridioides difficile colonization in children with inflammatory bowel disease.
J Pediatr Gastroenterol Nutr
December 2024
Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Monroe Carell Junior Children's Hospital at Vanderbilt, Nashville, Tennessee, USA.
Colonization by Clostridioides difficile is common in children with inflammatory bowel disease (IBD) and complicates both the management of IBD and the diagnosis of C. difficile infection (CDI). There is a paucity of data on rates, risk factors, and outcomes associated with asymptomatic C.
View Article and Find Full Text PDFGene Expression Dysregulation in Whole Blood of Patients with Infection.
Int J Mol Sci
November 2024
Department of Pharmacology and Therapeutics, Institute of Systems Molecular and Integrative Biology, University of Liverpool, Liverpool L69 3GL, UK.
() is a global threat and has significant implications for individuals and health care systems. Little is known about host molecular mechanisms and transcriptional changes in peripheral immune cells. This is the first gene expression study in whole blood from patients with infection.
View Article and Find Full Text PDFRisk of Clostridioides difficile infection in inflammatory bowel disease patients undergoing vedolizumab treatment: a systematic review and meta-analysis.
BMC Gastroenterol
October 2024
Department of Gastroenterology, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing Digestive Disease Center, Beijing Friendship Hospital, National Clinical Research Center for Digestive Disease, Capital Medical University, 95 Yong-an Road, Xi- cheng District, Beijing, China.
Background: Inflammatory bowel disease (IBD) is a chronic, relapsing condition wherein biologics have improved disease prognosis but introduced elevated infection susceptibility. Vedolizumab (VDZ) demonstrates unique safety advantages; however, a comprehensive systematic comparison regarding the risk of Clostridioides difficile infection (CDI) between vedolizumab and alternative medications remains absent.
Method: Medline, Embase, Cochrane, and clinicaltrials.
Genetic insight into the relationship between inflammatory bowel disease and infection.
mSphere
November 2024
Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan, USA.
Patients with inflammatory bowel disease (IBD) are at increased risk of infection (CDI). Herein, we aimed to determine if genetic risk contributes to this observed association. We carried out a genome-wide association study (GWAS) analysis in the Michigan Genomics Initiative and the United Kingdom Biobank for CDI based on ICD codes and meta-analyzed these results with similar publicly accessible GWAS summary statistics from Finngen.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!